drugset
drugset / Trial / NCT06020495

Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia

NCT06020495 ↗

Phase 3 Recruiting 260 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupOpen-labelTreatment

Summary

ICU patients with severe hyponatremia and a high risk of rapid SNa overcorrection.

Timeline

Start
2024-12-17
Primary completion
2026-09-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Desmopressin Peptide 4 ug Intravenous
Background sodium chloride Unknown 150 ml —

Indications

No indication recorded.